Molecular Biomarkers & Diagnosis

Fei Ye

Fei Ye
Department of Pathology
Mount Sinai School of Medicine, USA

Biography

Dr. Ye’s presently working in the department of Pathology, Mount Sinai School of Mediicne, USA. Research work had been focus on plant-derived agents and their anti-cancer activity and their molecular mechanism since 1995.

Research Interest

Dr. Ye’s research work had been focus on plant-derived agents and their anti-cancer activity and their molecular mechanism since 1995. One such drug, SBX, can inhibit NSCLC cell growth in vitro and in animals, and SBX directly targets the ERK pathway. More significantly, SBX is more potent and much tolerable than carboplatin, a most effective drug for NSCLC. Combination of SBX with carboplatin can synergistically increase the potency of their anticancer activity, probably acting cooperatively on different anti-proliferation mechanisms. Dr. Ye Also has a strong interest in drug and diagnostic marker discovery. In order for searching biomarkers and drugable targets for cancer diagnosis and treatment, Dr. Ye recently developed a novel Protein Pathway Array Technology (http://www.celldiv.com/content/4/1/20). The Pathway Array technology is an innovative proteomic assay that allows screen globally the changes in protein expression and phosphorylation. The focus of Protein Pathway Array is to determine the signaling networks that related to proliferation, apoptosis, angiogenesis, invasion and metastasis. Using this technology, Dr. Ye and her group identified several promising protein biomarkers for cancer diagnosis, molecular staging and prognosis.